부산대학교 도서관

BackgroundImmune checkpoint inhibitors have demonstrated efficacy in the treatment of classical Hodgkin’s lymphoma (cHL). We analyzed the efficacy and safety of pembrolizumab or nivolumab in patients with pretreated cHL. MethodsClinical data from the cancer chemotherapy registry of Samsung Medical Center were retrospectively analyzed to study patients with cHL treated with pembrolizumab or nivo-lumab between Oct 2015 and Dec 2018. ResultsOf the 20 patients, seven (35%) were enrolled in the study after a relapse following autolo-gous hematopoietic stem cell transplantation (ASCT) and 12 (60%) after a relapse follow-ing receipt of brentuximab vedotin (BV). Sixteen (80%) patients received pembrolizumab, and four (20%) patients received nivolumab. The complete remission rate was 45% (9/20), and 30% (6/20) of patients achieved partial remission, for an overall response rate (RR) of 75% [15/20; 95% confidence interval (CI), 34.7‒93.3]. With a median follow-up dura-tion of 14 months, the median PFS was 18 months (95% CI, 2.4‒33.5 mo), and the median OS was 36 months [95% CI, 36-not applicable (NA) mo]. Pembrolizumab and nivolumab were generally well tolerated.ConclusionIn this study, pembrolizumab and nivolumab both demonstrated clinical efficacy and tol-erability in patients with cHL who failed previous chemotherapy or ASCT.